Allergan plc (NYSE:AGN) [Trend Analysis] retains strong position in active trade, as shares scoring -0.42% to $238.44 in active trade session, while looking at the shares volume, around 225708 shares have changed hands in this session. Allergan plc (AGN) as well as Editas Medicine, Inc. (EDIT) reported that a strategic research and development alliance under which Allergan will receive exclusive access and the option to license up to five of Editas Medicine’s genome-editing ocular programs, including its lead program for Leber Congenital Amaurosis (LCA10), which is currently in pre-clinical development.
Editas Medicine will receive an upfront payment of $90 million for the development of five candidate programs. Allergan will be responsible for development and commercialization of the optioned products, subject to Editas’ option right to co-develop and co-promote up to two optioned products in the United States.
The contract covers early stage, first-in-class ocular programs based on Editas Medicine’s CRISPR genome editing platform, including CRISPR/Cas9 and CRISPR/Cpf1. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a versatile tool that can be programmed to target specific stretches of genetic code and edit DNA at precise locations in the human genome. The firm has institutional ownership of 93.10%, while insider ownership included 0.10%. AGN attains analyst recommendation of 2.00 with week’s performance of -0.06%. Investors looking further ahead will note that the Price to next year’s EPS is 11.20%.
Endo International plc (NASDAQ:ENDP) [Trend Analysis] knocking active thrust in leading trading session, shares a decrease of -0.73% to 10.15 with around 3.11 Million shares have changed hands in this session. The benefits of Endo International Plc’s long-acting opioid painkiller no longer outweigh its risks, an independent panel to the U.S. Food and Drug Administration (FDA) concluded on Tuesday.Opioid abuse, overdose and addiction have assumed epidemic proportions in the United States, partly due to unrestricted prescription of narcotic painkillers as well as the paucity of access to substance-abuse treatment programs.The panel was called to upon to address the high abuse rate of Endo’s Opana ER, a long-acting variation of oxymorphine, and other oxymorphone products. The stock is going forward its fifty-two week low with 1.35% and lagging behind from its 52-week high price with -75.24%.
Similar, the positive performance for the quarter recorded as -34.65% and for the year was -75.71%, while the YTD performance remained at -37.95%. ENDP has Average True Range for 14 days of 0.66.